Range Financial Group LLC Acquires Shares of 19,986 Hims & Hers Health, Inc. $HIMS

Key Points

• Range Financial Group LLC invested approximately $996,000 in Hims & Hers Health, purchasing 19,986 shares during the second quarter.
• Hims & Hers Health reported a net margin of 9.63% and revenue of $544.83 million for the quarter, which was up 72.6% year-over-year.
• After recent insider sales, 17.71% of Hims & Hers Health's stock is owned by company insiders, with CEO Andrew Dudum selling 660,000 shares for approximately $33.38 million.

Range Financial Group LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 19,986 shares of the company's stock, valued at approximately $996,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health in the first quarter valued at $30,000. UMB Bank n.a. raised its stake in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after buying an additional 933 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Hims & Hers Health in the first quarter valued at $41,000. Larson Financial Group LLC raised its stake in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after buying an additional 458 shares in the last quarter. Finally, Webster Bank N. A. raised its stake in Hims & Hers Health by 229.1% in the second quarter. Webster Bank N. A. now owns 905 shares of the company's stock valued at $45,000 after buying an additional 630 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of analyst reports. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Morgan Stanley restated an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Finally, Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Stock Performance

HIMS traded up $1.54 during trading on Friday, reaching $57.74. The company's stock had a trading volume of 36,152,647 shares, compared to its average volume of 27,039,632. Hims & Hers Health, Inc. has a 52-week low of $15.73 and a 52-week high of $72.98. The company's fifty day moving average price is $50.71 and its 200-day moving average price is $45.66. The company has a market capitalization of $13.05 billion, a price-to-earnings ratio of 72.18, a price-to-earnings-growth ratio of 3.80 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same period in the prior year, the firm posted $0.06 EPS. Hims & Hers Health's revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Irene Becklund sold 8,410 shares of the business's stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $424,705.00. Following the sale, the insider owned 1,418 shares of the company's stock, valued at $71,609. The trade was a 85.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business's stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $506,060.50. Following the sale, the insider directly owned 169,940 shares in the company, valued at $8,581,970. This trade represents a 5.57% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,535,085 shares of company stock worth $78,035,921. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.